BioAge Labs, Inc. (BIOA) Gets a Buy from Citi

BioAge Labs Gains on Positive BGE-102 Clinical-Trial Data

BioAge Labs announces additional interim data from Phase 1 trial of BGE-102

Bioage Announces Additional Positive Interim Phase 1 Data For BGE-102, A Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential For Best-In-Class Hscrp Reduction In Participants With Ele

Bioage Announces Additional Positive Interim Phase 1 Data for Bge-102, a Novel Brain-Penetrant Nlrp3 Inhibitor, Demonstrating Potential for Best-in-Class Hscrp Reduction in Participants With Elevated Cardiovascular Risk

Bioage Labs Inc - Phase 1 Data Anticipated 1H 2026; Phase 2a Study to Initiate 1H 2026

Bioage Labs Inc: Bge-102 Was Well Tolerated With a Favorable Safety Profile

BioAge Labs Reports BGE-102 Achieves 86% hsCRP Reduction in Phase 1 Trial

BioAge Labs Granted Patent Covering Novel NLRP3 Inhibitor Composition and Binding Site

BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares

BioAge Labs Raised to Equal-Weight From Underweight by Morgan Stanley

BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares

BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102

Bioage Labs Inc - Bge-102 Well-Tolerated in Sad and Initial Mad Cohorts, With a Pharmacokinetic Profile Supporting Once-Daily Oral Dosing

Bioage Labs Inc - Announces Positive Interim Phase 1 Data for Bge-102, a Novel Brain-Penetrant Nlrp3 Inhibitor

BioAge Labs Reports Positive Interim Phase 1 Results for BGE-102 NLRP3 Inhibitor

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

BioAge Labs Advances Clinical Programs Amid Financial Progress

Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M

BioAge Labs Doses First Participant in BGE-102 Phase 1 Trial and Reports $2.1 Million Q3 Collaboration Revenue